SpyGlass Pharma Secures $75 Million Series D Financing to Advance Long-Term Glaucoma Drug Delivery Platform

SpyGlass Pharma 获得 7500 万美元 D 轮融资，推进长期青光眼药物递送平台的发展

June 03, 2025

2025年6月3日

SpyGlass Pharma has closed a $75 million Series D financing round to support the continued development of its proprietary long-acting drug delivery platform. This funding will be directed toward advancing pivotal phase 3 clinical trials and accelerating efforts to address unmet needs in the long-term treatment of glaucoma and other chronic ophthalmic diseases..

SpyGlass Pharma已完成7500万美元的D轮融资，以支持其专有的长效药物递送平台的持续开发。这笔资金将用于推进关键的3期临床试验，并加速解决青光眼及其他慢性眼科疾病长期治疗中的未满足需求。

A Novel Approach to Sustained Glaucoma Therapy

一种持续性青光眼治疗的新方法

SpyGlass Pharma’s innovative platform is designed to deliver bimatoprost—a well-established therapy for intraocular pressure (IOP) reduction—over a three-year period. The device is implanted during routine cataract surgery and targets tissues involved in IOP regulation, offering a potentially transformative alternative to daily eye drops and other standard treatments..

SpyGlass Pharma的创新平台旨在三年内递送比马前列素——一种已确立的降低眼内压（IOP）的疗法。该装置在常规白内障手术中植入，针对参与眼内压调节的组织，提供了一种可能替代每日滴眼液及其他标准治疗的变革性选择。

Strong Financial Support from Leading Healthcare Investors

领先的医疗保健投资者提供强大的财务支持

The Series D round was led by Sands Capital and included participation from Gilde Healthcare, alongside returning investors:

D轮融资由Sands Capital领投，Gilde Healthcare参与，还包括以下回归的投资者：

• New Enterprise Associates (NEA)

• 新企业联合公司 (NEA)

• RA Capital

• RA资本

• Vensana Capital

• 云杉资本

• Samsara BioCapital

• 轮回生物资本

• Vertex Ventures HC

• 顶点创投HC

“We appreciate the strong support from our new and existing investors, underscoring their confidence in our innovative Drug Delivery Platform,” said Patrick Mooney, CEO of SpyGlass Pharma.

“我们感谢新老投资者的大力支持，这充分表明了他们对我们创新的药物递送平台的信心，”SpyGlass Pharma首席执行官Patrick Mooney表示。

“We are excited to advance our platform through pivotal phase 3 trials as we accelerate our commitment to addressing significant unmet needs for ophthalmic patients.”

“我们很高兴通过关键的第三阶段试验推进我们的平台，因为我们正在加速实现解决眼科患者重大未满足需求的承诺。”

Clinical Development Progress

临床开发进展

In November 2024, SpyGlass completed enrollment in its phase 1/2 randomized, multi-center clinical trial (NCT06120842), evaluating the safety and efficacy of the bimatoprost delivery platform in patients with glaucoma or ocular hypertension.

2024年11月，SpyGlass完成了其1/2期随机、多中心临床试验（NCT06120842）的入组工作，该试验评估了比马前列素递送平台在青光眼或高眼压患者中的安全性和有效性。

“The long-term safety and efficacy demonstrated from both the first-in-human feasibility trial and the phase 2, multi-center, randomized clinical trial showed significant and sustained intraocular pressure-lowering in glaucoma patients,” noted Malik Y. Kahook, MD, Co-founder and President of SpyGlass Pharma..

“首次人体可行性试验和第二阶段多中心随机临床试验所展示的长期安全性和有效性表明，青光眼患者的持续性眼压显著且持续降低，”SpyGlass Pharma联合创始人兼总裁Malik Y. Kahook博士指出。

Upcoming Milestones

即将达成的里程碑

• 24-month follow-up data from the ongoing trial will be presented at the American Academy of Ophthalmology (AAO) meeting in October 2025.

• 正在进行的试验的24个月随访数据将在2025年10月的美国眼科学会（AAO）会议上公布。

• The company plans to collaborate closely with the U.S. Food and Drug Administration (FDA) to progress toward phase 3 trials and pursue potential commercial approval.

• 该公司计划与美国食品和药物管理局 (FDA) 紧密合作，推进至第三阶段试验，并寻求潜在的商业批准。

SpyGlass Pharma’s platform represents a potential shift in glaucoma treatment by offering a sustained, minimally invasive drug delivery method designed for long-term IOP control.

SpyGlass Pharma的平台通过提供一种持续、微创的药物递送方法，旨在实现长期的眼压控制，代表了青光眼治疗的潜在转变。